Table 5.
Seropositivity analysis of JDM patients and HC at each study visit
| Baseline visit | |||||||
| JDM A (n = 10) | JDM B (n = 13) | JDM C (n = 14) | p-value | JDM Total (n = 37)a | HC (n = 39)a | p-value | |
| HPV 16, n (%) | 1 (10.0) | 6 (46.0) | 3 (21.0) | 0.142 | 10 (27.0) | 2 (5.0) | 0.012 |
| HPV 18, n (%) | 1 (10.0) | 4 (31.0) | 4 (29.0) | 0.571 | 9 (24.0) | 1 (3.0) | 0.006 |
| After the second qHPV vaccine dose | |||||||
| JDM A (n = 10) | JDM B (n = 11) | JDM C (n = 15) | p-value | JDM Total (n = 36)b | HC (n = 14)c | p-value | |
| HPV 16, n (%) | 10 (100) | 10 (91.0) | 14 (93.0) | 1.000 | 34 (94.0) | 14 (100) | 1.000 |
| HPV 18, n (%) | 10 (100) | 10 (91.0) | 13 (87.0) | 0.770 | 33 (92.0) | 14 (100) | 0.265 |
| After the thrid qHPV vaccine dose | |||||||
| JDM A (n = 8) | JDM B (n = 11) | JDM C (n = 12) | p-value | JDM Total (n = 31)b | HC (n = 31)c | p-value | |
| HPV 16, n (%) | 8 (100) | 11 (100) | 12 (100) | – | 31 (100) | 31 (100) | 1.000 |
| HPV 18, n (%) | 8 (100) | 11 (100) | 11 (92.0) | 1.000 | 30 (97.0) | 31 (100) | 1.000 |
| Six months after the third qHPV vaccine dose | |||||||
| JDM A (n = 5) | JDM B (n = 7) | JDM C (n = 5) | p-value | JDM Total (n = 17)b | HC | p-value | |
| HPV 16, n (%) | 5 (100) | 6 (86.0) | 5 (100) | 1.000 | 16 (94.0) | NA | NA |
| HPV 18, n (%) | 5 (100) | 6 (86.0) | 5 (100) | 1.000 | 16 (94.0) | NA | NA |
JDM juvenile dermatomyositis, HC healthy controls, HPV human papillomavirus, qHPV quadrivalent HPV vaccine, NA not applicable
aFive patients and two HC who had received doses of the vaccine before the study inclusion were excluded from this analysis
bForty-two JDM patients completed the 3-dose vaccination schedule, however blood samples were collected only from 36 patients after the second dose, 31 after the third dose, and 17 6 months after the third dose
cThirty-five HC completed the 3-dose vaccination schedule; however, blood samples were collected only from 14 HC after the second dose, and 31 after the third dose